Spexis AG
SIX:SPEX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Spexis AG
Net Income (Common)
Spexis AG
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Spexis AG
SIX:SPEX
|
Net Income (Common)
-CHf19.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Net Income (Common)
-$581.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-37%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Net Income (Common)
CHf40.2m
|
CAGR 3-Years
49%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Net Income (Common)
-CHf111.7m
|
CAGR 3-Years
49%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Net Income (Common)
CHf2.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Net Income (Common)
-CHf17m
|
CAGR 3-Years
28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Spexis AG
Glance View
Spexis Ltd. is clinical stage biopharmaceutical company, which engages in the research and development of macrocycle drugs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2018-05-15. The firm focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The firm's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
See Also
What is Spexis AG's Net Income (Common)?
Net Income (Common)
-19.6m
CHF
Based on the financial report for Dec 31, 2023, Spexis AG's Net Income (Common) amounts to -19.6m CHF.
What is Spexis AG's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
17%
Over the last year, the Net Income (Common) growth was -6%. The average annual Net Income (Common) growth rates for Spexis AG have been 24% over the past three years , 17% over the past five years .
